Venenum Biodesign LLC has reported new substituted phenylsulfonamides acting as 2-acylglycerol O-acyltransferase 2 (MOGAT2) inhibitors described as potentially useful for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD) and obesity.

The Research Foundation of State University of New York has patented toxoids reported to be useful for the treatment of cancer.

Clinch Biosciences LLC has divulged myosin-2 (MYH2) inhibitors reported to be useful for the treatment of stroke, hypertension, acute kidney injury, gastrointestinal motility disorders and myocardial infarction.

Shenzhen Salubris Pharmaceuticals Co. Ltd. has discovered new proprotein convertase subtilisin/kexin-type 9 (PCSK9) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase dual inhibitors. They are described as potentially useful for the treatment of hypercholesterolemia.

Abbisko Therapeutics Co. Ltd. has synthesized new GTPase KRAS G12V and G12D mutant inhibitors designed for use in the treatment of cancer.

Tyk Medicines Inc. has identified N-acetyl-β-D-glucosaminidase (O-GlcNAcase; OGA) inhibitors described as potentially useful for the treatment of cancer, metabolic diseases, Alzheimer’s disease and progressive supranuclear palsy.

Researchers from the Institut National De La Sante Et De La Recherche Medicale, Universite de Bordeaux and Universite de Paris Cite have reported indane 1,3-dione derivatives acting as furin (PACE; PCSK3) inhibitors potentially useful for the treatment of cancer.

Jeil Pharmaceutical Co. Ltd. has disclosed dihydrothiopyranopyrimidine compounds acting as phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of inflammatory joint disease, neurological disorders and more.

Yichang Humanwell Pharmaceutical Co. Ltd. has identified compounds acting as potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators. They are reported to be useful for the treatment of amyotrophic lateral sclerosis, depression, epilepsy, stroke, multiple sclerosis, pain, and Alzheimer’s and Parkinson’s disease, among others.

Chengdu Brilliant Pharmaceutical Co. Ltd. and Chengdu Xinke Pharmaceutical Co. Ltd. have disclosed drug conjugates comprising a bone-targeting moiety covalently bound to a radiolabeled-chelating agent through a linker acting as positron emission tomography (PET)/single-photon emission computerized tomography (SPECT) imaging agents. They are reported to be useful for diagnosis and treatment of bone disorders.